EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Association of serum fetuin-A levels with mortality in dialysis patients


Kidney International 72(2): 202-207
Association of serum fetuin-A levels with mortality in dialysis patients
Calcifying atherosclerosis is an active process, which is controlled by calcification inhibitors and inducers. Fetuin-A, an acute phase glycoprotein, is one of the more powerful circulating inhibitors of hydroxyapatite formation. A prospective multicenter cohort study was initiated to include both hemodialysis (HD) and peritoneal dialysis (PD) patients in an evaluation of the association of serum fetuin-A levels with both cardiovascular (CV) and non-CV mortality. An increase in the serum fetuin-A concentration of 0.1 g/l was associated with a significant reduction in all-cause mortality of 13%. There was a significant 17% reduction in non-CV mortality and a near significant reduction in CV mortality. This association of fetuin-A and mortality rates was comparable in both HD and PD patients even when corrected for factors, including but not limited to age, gender, primary kidney disease, C-reactive protein levels, and nutritional status. We conclude that serum fetuin-A concentrations may be a general predictor of mortality in dialysis patients.

(PDF same-day service: $19.90)

Accession: 015093079

PMID: 17342178

DOI: 10.1038/sj.ki.5002178



Related references

Cardiovascular mortality in dialysis patients Evidence that low Ahsg/fetuin serum levels may be a critical factor. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 219A, September, 2002

Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361(9360): 827-833, 2003

Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrology, Dialysis, Transplantation 24(4): 1232-1237, 2008

The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry. Plos One 10(11): E0143430-E0143430, 2016

Serum fetuin-A levels, QT dispersion and P dispersion in dialysis patients. Renal Failure 35(4): 477-482, 2013

Association of low serum fetuin A levels with poor arteriovenous access patency in patients undergoing maintenance hemodialysis. American Journal of Kidney Diseases 56(4): 720-727, 2010

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases 52(3): 519-530, 2008

Association between serum fetuin-A levels, carotid artery stiffness, and intima-media thickness in patients with normotensive obstructive sleep apnea syndrome. Angiology 65(7): 607-613, 2015

Deficiency of the calcification inhibitor Ahsg/fetuin predicts mortality in dialysis patients. Nephrology Dialysis Transplantation 17(Abstracts Supplement 1): 13, 2002

The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrology, Dialysis, Transplantation 21(10): 2881-2892, 2006